Safety and Efficacy of Sunitinib Given in Schedule Modification in Patients with Advanced Renal Cell Carcinoma (RCC)
Not Applicable
Recruiting
- Conditions
- Renal Cell Carcinoma
- Registration Number
- JPRN-UMIN000011649
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 132
Inclusion Criteria
Not provided
Exclusion Criteria
Diagnosis of any secondary malignancy Patients who are judged by an investigator to be inappropriate for this study for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment discontinuation rate due to unacceptable toxicities and relative dose intensity within 6 weeks (within 1 course) Duration of treatment and progression free-survival
- Secondary Outcome Measures
Name Time Method –Objective response rate –Quality of life